A small open-label study in Sweden tested ATR-258, a new drug candidate from Atrogi, in 13 participants over eight weeks, observing reductions in fat mass alongside increases in lean body mass and improved leg strength. The trial lacked a placebo control and was not designed to confirm efficacy, but researchers noted favorable changes in body composition that contrast with common side effects of current obesity medications. ATR-258 is being developed to counteract muscle loss often seen with weight-loss drugs like GLP-1 receptor agonists.
The study aimed to assess whether ATR-258 could preserve or build lean mass while promoting fat reduction, a key challenge in obesity treatment where up to 45% of weight lost on existing therapies may come from muscle. Participants received daily doses of the experimental pill, and researchers measured changes using imaging and strength tests. While fat decreased, lean mass increased significantly, and leg power improved, suggesting a dual benefit not typically seen with incretin-based medicines. Atrogi highlighted these results as preliminary but encouraging, especially given the absence of a control group and short duration.
Early data from Atrogi’s trial suggest ATR-258 may shift the balance of weight loss toward fat rather than muscle, addressing a major drawback of current obesity drugs. Unlike semaglutide or tirzepatide, which primarily reduce appetite and calorie intake, ATR-258 appears to influence metabolic pathways tied to muscle preservation. However, scientists caution that the open-label design and small sample size limit conclusions, and larger, placebo-controlled trials are needed to verify these effects. The company plans to advance ATR-258 into longer studies with more diverse participants to assess safety and sustained impact.
Persistent muscle loss during weight reduction can lower metabolic rate, reduce physical function, and increase the risk of weight regain, undermining long-term health goals. Maintaining lean mass is especially important for older adults and those with mobility limitations, where strength directly affects independence. If ATR-258 or similar compounds prove effective, they could be used alongside existing obesity drugs to improve the quality of weight loss. This combination approach might help patients lose fat while retaining or gaining strength, potentially improving outcomes in chronic weight management.
What is ATR-258 and how does it work? ATR-258 is an investigational drug being developed by Atrogi to target pathways involved in muscle metabolism and fat regulation, aiming to promote fat loss while preserving or increasing lean mass during weight reduction.
Why is muscle loss a concern with current obesity drugs? Studies indicate that 25–45% of weight lost on medications like GLP-1 agonists may come from lean mass, which can slow metabolism and reduce physical strength, making long-term weight maintenance more difficult.
What are the next steps for ATR-258? Atrogi plans to conduct larger, placebo-controlled trials to confirm the initial findings, evaluate safety over longer periods, and determine the drug’s potential role in combination therapies for obesity.